VERA Stock Summary and Trading Ideas (Vera Therapeutics - Class A | NASDAQ:VERA)

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.

As of June 12, 2026, VERA stock price climbed to $34.26 with 852,757 million shares trading.

VERA has a beta of 1.44, meaning it tends to be more sensitive to market movements. VERA has a correlation of 0.08 to the broad based SPY ETF.

VERA has a market cap of $2.46 billion. This is considered a Mid Cap stock.

In the last 3 years, VERA traded as high as $56.05 and as low as $8.90.

The top ETF exchange traded funds that VERA belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

VERA has outperformed the market in the last year with a return of +52.1%, while the SPY ETF gained +24.1%. However, in the most recent history, VERA shares have underperformed the stock market with its stock returning -16.8% in the last 3 month period and -3.5% for the last 2 week period, while SPY has returned +11.6% and -1.9%, respectively.

VERA support price is $32.12 and resistance is $35.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.